

References

I-9233

1. Oxlummo prescribing information. Alnylam Pharmaceuticals, Inc. October 2022September 2023.
2. Cochat P, Hulton SA, Acquaviva C, et al. Primary Hyperoxaluria Type 1: Indications for Screening and Guidance for Diagnosis and Treatment. *Nephrol Dial Transplant*. 2012;27:1729-1736.
3. Hulton SA. The Primary Hyperoxalurias: A Practical Approach to Diagnosis and Treatment. *Int J Surg*. 2016 Dec;36(D):649-654.
4. Hoppe B, Beck BB, Milliner D. The Primary Hyperoxalurias. *Kidney Int*. 2009 Jun;75(12):1264-1271.
5. Niaudet P, et al. Primary Hyperoxaluria. UpToDate. Literature review current through January 2023. Last updated June 2022.Milliner DS, Cochat P, Hulton SA. Plasma oxalate and eGFR are correlated in primary hyperoxaluria patients with maintained kidney function-data from three placebo-controlled studies. *Pediatr Nephrol*. 2021;36(7):1785.